Gilbert H. Kliman Sells 3,000 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the sale, the director now owns 32,336 shares in the company, valued at approximately $4,225,345.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Glaukos Stock Up 0.6 %

Shares of GKOS stock opened at $126.27 on Friday. The firm’s 50-day moving average is $124.31 and its 200-day moving average is $109.75. The stock has a market cap of $6.36 billion, a price-to-earnings ratio of -43.84 and a beta of 1.03. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.67 and a current ratio of 5.48. Glaukos Co. has a 52-week low of $59.22 and a 52-week high of $136.60.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, hitting analysts’ consensus estimates of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The firm had revenue of $95.70 million during the quarter, compared to analysts’ expectations of $88.86 million. During the same period in the previous year, the business posted ($0.55) earnings per share. The company’s revenue for the quarter was up 19.0% compared to the same quarter last year. Sell-side analysts predict that Glaukos Co. will post -2.18 EPS for the current year.

Analyst Ratings Changes

GKOS has been the subject of a number of research reports. Wells Fargo & Company raised their price target on shares of Glaukos from $120.00 to $135.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Needham & Company LLC increased their price target on shares of Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Morgan Stanley lifted their target price on Glaukos from $100.00 to $120.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Citigroup lowered shares of Glaukos from a “buy” rating to a “neutral” rating and lifted their price target for the company from $130.00 to $132.00 in a research note on Wednesday, July 10th. Finally, BTIG Research upped their price objective on Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus target price of $129.82.

Hedge Funds Weigh In On Glaukos

A number of large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its stake in shares of Glaukos by 3.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 923,526 shares of the medical instruments supplier’s stock valued at $73,412,000 after acquiring an additional 31,213 shares in the last quarter. Norges Bank acquired a new stake in shares of Glaukos during the 4th quarter worth approximately $28,807,000. Nomura Holdings Inc. increased its stake in shares of Glaukos by 3.2% in the 4th quarter. Nomura Holdings Inc. now owns 232,034 shares of the medical instruments supplier’s stock valued at $18,444,000 after purchasing an additional 7,146 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Glaukos in the second quarter valued at about $6,832,000. Finally, Natixis bought a new stake in shares of Glaukos during the 1st quarter valued at approximately $614,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.